logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Tenaya Therapeutics, Inc.


USPTO Granted Patents = 19


Forward Citations = 18

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Laura Lombardi (8 out of 8 patents)

silverMedal Huanyu Zhou (5 out of 5 patents)

bronzeMedal Christopher A Reid (5 out of 5 patents)

4.  Mohammad A Mandegar (4 out of 4 patents)

5.  Ulhas Bhatt (3 out of 8 patents)

6.  David Sperandio (3 out of 4 patents)

7.  Alok Nerurkar (3 out of 6 patents)

8.  Snahel Patel (3 out of 33 patents)

9.  Tien Widjaja (3 out of 8 patents)

10.  Julio Cesar Medina (3 out of 73 patents)

11.  Zhihong Jane Yang (2 out of 2 patents)

12.  Frederick Seidl (1 out of 4 patents)

13.  Pingyu Ding (1 out of 50 patents)

14.  Jin Yang (1 out of 1 patent)

15.  Chris Reid (1 out of 1 patent)


19 patents:

1. 12766199 - GENE THERAPY VECTORS FOR TREATING HEART DISEASE (2026-10-20),
2. 12630841 - Adeno-associated virus with engineered capsid (2026-05-19),
3. 12576161 - PLAKOPHILLIN-2 GENE THERAPY METHODS AND COMPOSITIONS (2026-03-17),
4. 12564647 - OPTIMIZED EXPRESSION CASSETTES FOR GENE THERAPY (2026-03-03),
5. 12552838 - ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSID (2026-02-17),
6. 12478691 - Gene therapy vectors for treating heart disease (2025-11-25),
7. 12312345 - Fluoroalkyl-oxadiazoles and uses thereof (2025-05-27),
8. 12201617 - HDAC6 inhibitors for treatment of metabolic disease and HFpEF (2025-01-21),
9. 12168778 - Cardiac cell reprogramming with myocardin and ASCL1 (2024-12-17),
10. 12151001 - Optimized expression cassettes for gene therapy (2024-11-26),
11. 12104165 - Adeno-associated virus with engineered capsid (2024-10-01),
12. 11926622 - Fluoroalkyl-oxadiazoles and uses thereof (2024-03-12),
13. 11913012 - Cardiac cell reprogramming with myocardin and ASCL1 (2024-02-27),
14. 11781156 - Plakophillin-2 gene therapy methods and compositions (2023-10-10),
15. 11759531 - Gene therapy vectors for treating heart disease (2023-09-19),
Company Overview
Tenaya Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease. The company specializes in gene therapy and regenerative medicine, aiming to address the underlying causes of cardiac conditions. By leveraging advanced scientific research and technology, Tenaya is dedicated to transforming the treatment landscape for patients with cardiovascular diseases, striving to improve outcomes and enhance quality of life.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

19 Patents

#68 in South San Francisco, CA

#4,105 in California

#17,150 in US

#32,693 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Tenaya Therapeutics, Inc.

Forward Citations = 18

25 inventors:

goldMedal Laura Lombardi (8 out of 8 patents)

silverMedal Huanyu Zhou (5 out of 5 patents)

bronzeMedal Christopher A Reid (5 out of 5 patents)

4.  Mohammad A Mandegar (4 out of 4 patents)

5.  Ulhas Bhatt (3 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Tenaya Therapeutics, Inc.. Retrieved from https://idiyas.com/company/tenaya-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…